A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
Public ClinicalTrials.gov record NCT06425302. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
Study identification
- NCT ID
- NCT06425302
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Celgene
- Industry
- Enrollment
- 90 participants
Conditions and interventions
Conditions
Interventions
- Bendamustine Drug
- Cyclophosphamide Drug
- Doxorubicin Drug
- Golcadomide Drug
- Prednisone Drug
- Rituximab Drug
- Vincristine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 29, 2024
- Primary completion
- Nov 22, 2026
- Completion
- Nov 26, 2028
- Last update posted
- Jan 7, 2026
2024 – 2028
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0152 | Birmingham | Alabama | 35294-3300 | — |
| Local Institution - 0055 | Anchorage | Alaska | 99508 | — |
| Local Institution - 0180 | Phoenix | Arizona | 85054 | — |
| Local Institution - 0190 | Tucson | Arizona | 85711 | — |
| Local Institution - 0035 | San Francisco | California | 94143 | — |
| Local Institution - 0022 | Washington D.C. | District of Columbia | 20007 | — |
| Local Institution - 0209 | Fort Myers | Florida | 33901 | — |
| Local Institution - 0005 | Jacksonville | Florida | 32224 | — |
| Local Institution - 0210 | St. Petersburg | Florida | 33705 | — |
| Local Institution - 0026 | Tampa | Florida | 33606 | — |
| Local Institution - 0208 | West Palm Beach | Florida | 33401 | — |
| Local Institution - 0019 | Westwood | Kansas | 66205 | — |
| Local Institution - 0031 | Rochester | Minnesota | 55905 | — |
| Local Institution - 0111 | Henderson | Nevada | 89074 | — |
| Local Institution - 0183 | Hackensack | New Jersey | 07601 | — |
| Local Institution - 0052 | Salt Lake City | Utah | 84106 | — |
| Local Institution - 0201 | Norfolk | Virginia | 23502 | — |
| Local Institution - 0202 | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06425302, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 7, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06425302 live on ClinicalTrials.gov.